Zurzuvae is accessible and can treat symptoms more quickly and effectively
The Food and Drug Administration approved a first-of-its-kind pill on Aug. 4 to treat postpartum depression. The news represents a potential breakthrough in the treatment of a condition that in recent years has become one of the leading causes of maternal mortality in the United States.
Given this advancement, clinicians were asked what pregnant people and their families should know both about Zurzuvae, its symptoms and its treatment of postpartum depression.The early days of parenthood will make most feel overwhelmed and not themselves. Some of the symptoms of depression common in new mothers include changes in appetite and sleep.
An important caveat is that the clinical trials have primarily included women with severe postpartum depression, not those experiencing the more common range of symptoms that are more mild or moderate, said Catherine Monk, a professor of medical psychology at Columbia University. For that latter group, Monk said nonmedical interventions like therapy and lifestyle changes aimed at lowering anxiety levels may be more suitable.
Blanc said this drug alone won’t solve the problem of maternal mental health, which has to be addressed more comprehensively by patients and their health care providers.
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA Approves First RSV Vaccine For Kids—Given To Pregnant Moms—Here’s What To KnowRSV infects nearly every child by the time they reach 2 and can cause serious, potentially fatal, illness.
Read more »
On Abortion Pills, Federal Appeals Court Prescribes Justice for FDAAmericans concerned about the safety, health, and welfare of women and girls in this country received welcome news last week.
Read more »
Regeneron shares climb after FDA approval of macular degeneration treatmentShares of Regeneron Pharmaceuticals Inc. gained 1.4% premarket on Monday after the company said late Friday that the U.S. Food and Drug Administration had...
Read more »
Neurocrine Biosciences price target raised at Oppenheimer after FDA approves movement disorder treatmentNeurocrine Biosciences Inc. said Friday that the U.S. Food and Drug Administration has approved Ingrezza for treatment of an involuntary movement disorder...
Read more »
Gilead says FDA hits pause on study of leukemia treatmentGilead Sciences Inc. said Monday that the U.S. Food and Drug Administration has put a partial clinical hold on U.S. studies evaluating a treatment for acute...
Read more »
Regeneron Stock-Price Targets Rise as FDA Approves Higher Dose of Eye DrugThe Food and Drug Administration approved 8-milligram doses of Eylea, a treatment for wet age-related macular degeneration.
Read more »